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Improving mortality of coronary surgery
Study conclusions are paradoxical
Editor—The findings of the study by
Bridgewater et al of improving mortality of
coronary surgery over the first four years of
independent practice in 15 surgeons are rel-
evant and clinically important.1 But aren’t
the conclusions paradoxical?
The authors report that mortality in
patients operated on by newly appointed
consultant surgeons is similar to mortality in
patients operated on by established consult-
ants. Yet new consultants experience a halv-
ing in mortality after four years when they
become established consultants. The reason
is that Bridgewater et al used their peers as
the benchmark to qualify the first statement,
and their own results for the second.
This modest group of surgeons have
underplayed their own good results that
become excellent after four
years; the final ratio of
observed mortality to
expected mortality of 0.36
compared with the additive
EuroSCORE is impressive.
Unfortunately, this affects the
conclusions. The advantage
that the authors used them-
selves as a benchmark for
established consultants
offers a more valid compari-
son. Case selection, operative
performance, and manage-
ment of postoperative com-
plications will inevitably be
more similar. If so, the conclusions would say
that mortality in patients operated on by
newly appointed consultants is twice that of
established surgeons (the authors using
themselves as internal controls).
The real yardstick would be the next 15
newly appointed surgeons to the Northwest
region comparing their results with estab-
lished surgeons, as these new consultants
would compare their initial results with a
lower Northwest average (because of the con-
tribution of this excellent newly appointed
cohort). In this way a more accurate compari-
son would be obtained to determine if the
results of newly appointed surgeons are on a
par with their established peers.
Eric Lim specialist registrar cardiothoracic surgery
Papworth Hospital NHS Trust, Papworth Everard,
Cambridge CB3 8RE
eric.lim@cvsnet.org
Competing interests: None declared.
1 Bridgewater B, Grayson AD, Au J, Hassan R, Dihmis WC,
Munsch C, et al. Improving mortality of coronary surgery
over first four years of independent practice: retrospective
examination of prospectively collected data from 15
surgeons. BMJ 2004;329:421. (21 August.)
Data analysis was not robust
Editor—Bridgewater et al present data and
draw conclusions that are incompatible.1 In
their study new consultants not only
performed as well as their senior colleagues
in general (observed mortal-
ity v expected mortality is
0.61 v 0.66) but considerably
outperformed them in years
3 and 4. The authors attrib-
uted this improved perform-
ance by new consultants to a
learning curve. Interestingly,
this trend was not observed
in high risk cases. This
contradicts conventional wis-
dom. The data analysis by
Bridgewater et al was not
robust enough to compare
the two groups of surgeons
accurately.
Data from new consultants may have
been more non-homogeneous than those
from senior surgeons in terms of surgical
techniques such as off-pump surgery, myo-
cardial protection, etc. EuroSCORE is inad-
equate to compare a non-homogeneous
mixture of surgical practice as it was
developed when surgical practice was more
uniform.
An alternative and more scientific
approach would have been through logistic
regression with variables for different surgical
techniques and computing propensity scores.
Quintile stratification of propensity scores
would have shown the variability in surgical
practice. Propensity score matching of
patients would have offered a more uniform
method of comparison. Odds ratios from a
secondary logistic regression on matched
pairs of patients would have offered an accu-
rate method of comparing the performance
of the two groups of surgeons.
Some in the specialty fear that the
learning curve may be obvious in high
risk, non-coronary surgery. A similar study
on non-coronary surgery is now imperative
to address its implications for patients’
confidence and surgeons’ training.
Sheka L C Reddy clinical fellow cardiothoracic surgery
Cardiothoracic Centre, Liverpool L14 3PE
REDDYLCS@aol.com
1 Bridgewater B, Grayson AD, Au J, Hassan R, Dihmis WC,
Munsch C, et al. Improving mortality of coronary surgery
over first four years of independent practice: retrospective
examination of prospectively collected data from 15
surgeons. BMJ 2004;329:421. (21 August.)
Authors’ reply
Editor—We dispute that the data presented
and conclusions drawn are incompatible or
that there is a paradox. We have some
specific responses the points raised.
We set out to test the hypothesis that
there was improvement in surgeon perform-
ance after appointment to independent prac-
tice, which was indeed detected by our
observations. This was seen on crude mortal-
ity but was more noticeable after risk
adjustment.We accept that all risk adjustment
methods have limitations and acknowledged
that in our manuscript. To understand
whether “new” surgeons perform as well as
older surgeons seems a valid hypothesis to
test, and that is why we chose to undertake
this comparison by using two groups.
The fact that the mortality seen during
the fourth year of practice is lower than that
of more established consultants is an
interesting finding and one that we cannot
answer from our existing studies. It may be
down to “true” surgical factors (implying
suboptimal performance in some more
experienced surgeons) or may be due to
limitations of existing risk models.
We agree with Reddy that a need exists
for this type of study in non-coronary
surgery, but we disagree with his views about
alternative techniques of analysis. Whether
surgeons operate on-pump or off-pump or
use multiple arterial grafts is down to surgi-
cal preference. The literature is still not deci-
sive on the benefits of either approach. The
hypotheses we were testing were not to look
at the influence of these factors, and to cor-
rect for them as he suggests would not have
helped us to reach clearer conclusions.
Ben Bridgewater consultant cardiac surgeon
South Manchester University Hospital, Manchester
M23 9LT
Ben.Bridgewater@smuht.nwest.nhs.uk
Antony D Grayson regional clinical information
analyst
Cardiothoracic Centre, Liverpool L14 3PE
Competing interests: None declared.
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Performance monitoring
should take costs to heart
Editor—The three papers on the perform-
ance of cardiac surgeons in the issue of 21
August show that expertise combined with
statistical thinking can lead to rational
performance monitoring without bullying
overtones, disputed targets, or misconceived
“naming and shaming.”1–5
Publicly naming individual surgeons as
“not meeting” even the 99.99% standard
proposed by Keogh et al remains problem-
atic if the underlying problem is commonly
discovered to be specific to a process or
organisation rather than a surgeon.3 Until an
empirical database exists that clearly per-
suades cardiac surgeons and the public that
resolutions from “taking a closer look”
under the proposed new monitoring
scheme are more likely to be surgeon
specific than institutional, politicians and
others should not publicly name the
surgeons whose results trigger taking a
closer look. Instead, report only that a closer
look is being taken, the results being fairly
and frankly reported at a specified date. The
Healthcare Commission should also reserve
the right to take a closer look, randomly as
well as responsively.
Cost effectiveness was missing in all of
the papers.5 How much did the original
review of data quality in 10 units cost, how
much did the national clinical audit support
programme in the NHS Information
Authority invest to incorporate and aug-
ment the Society of Cardiothoracic Sur-
geons’ database, and how much does the
appointment of local data managers cost
annually? What are the annual costs of flag-
ging patients for mortality, of analysing data
and validating results? Why—if a perform-
ance monitoring protocol was in place, as
recommended5—was the implementation
phase so underestimated that the first data
trickled into the central cardiac audit
database in October 2003, too late for the
production of validated, risk adjusted,
surgeon specific results in 2004?
The effectiveness of performance moni-
toring is more difficult to measure than its
costs, but costly performance monitoring
should be designed so that effectiveness can
be measured—one of 11 key recommenda-
tions of the Royal Statistical Society’s
working party on performance monitoring
in the public services.5
Sheila M Bird senior statistician
MRC Biostatistics Unit, Cambridge CB2 2SR
sheila.bird@mrc-bsu.cam.ac.uk
Competing interests: None declared.
1 Bridgewater B, Grayson AD, Au J, Hassan R, Dihmis WC,
Munsch C, et al. Improving mortality of coronary surgery
over first four years of independent practice: retrospective
examination of prospectively collected data from 15
surgeons. BMJ 2004;329:421. (21 August.)
2 Zamvar V. Reporting systems for cardiac surgery. BMJ
2004;329:413-4. (21 August.)
3 Keogh B, Spiegelhalter D, Bailey A, Roxburgh J, Magee P,
Hilton C. The legacy of Bristol: public disclosure of
individual surgeons’ results. BMJ 2004;329:450-4. (21
August.)
4 Campbell NC, Murchie P. Treating hypertension with
guidelines in general practice. BMJ 2004;329:523-4. (4
September.)
5 Royal Statistical Society Working Party on Performance
Monitoring in the Public Services. Performance indicators:
good, bad, and ugly. Available at: www.rss.org.uk/archive/
performance/index.html
Bypass surgery mortality is
blunt measure of performance
Editor—Kmietowicz reports that UK heart
surgeons are among the best in the world as
measured by crude mortality of isolated
coronary artery bypass surgery.1 This
marker of surgical performance is wide-
spread.
Imagine the following scenario. A
patient undergoing isolated bypass grafting
has an uneventful procedure. During clo-
sure, the systemic blood pressure drops, and
the electrocardiogram shows that the
patient is becoming ischaemic. Cardio-
pulmonary bypass is reintroduced rapidly,
but a further attempt to wean from
circulatory support is unsuccessful. The sur-
geon, who is subject to mandatory reporting
of such cases, notes the small and insignifi-
cant jet of mitral regurgitation seen on the
intraoperative transoesophageal echo. He
readministers cardioplegia and performs a
mitral valve repair. The patient dies, but the
death is not recorded on the surgeon’s
ledger, as no longer is the procedure an
isolated coronary artery graft case.
Corridor whispers imply that the above
vignette has occurred. I have written
previously on the potential negative conse-
quences of mandatory performance report-
ing.2 Patients will continue to be at risk of
being denied potentially life saving surgery
or worse, be inappropriately managed intra-
operatively while such blunt tools are used.
I am not opposed to my outcomes being
examined, but risk adjusted audit of my total
practice is the minimum standard that is
acceptable. This would go some way to
lessen the potential for harm for cardio-
thoracic surgeons but also, more impor-
tantly, for their patients.
Ian S Gilfillan cardiothoracic surgeon
Fremantle Hospital, Fremantle, WA 6160, Australia
ian.gilfillan@health.wa.gov.au
Competing interests: None declared.
1 Kmietowicz Z. UK heart surgeons are among the best in
the world. BMJ 2004;329:644. (18 September.)
2 Gilfillan IS. Ranking heart surgeons has pitfalls. BMJ
2003;327:107-b.
Adverse events reporting in
English hospital statistics
Vague numbers are being perpetuated
Editor—Aylin et al write in their Dr Foster’s
case notes that about 850 000 medical
errors occur in NHS hospitals every year,
resulting in 40 000 deaths.1 They reference
this to a PowerPoint presentation (itself
unreferenced) given in Australia in 2001.
The figures appear in Organisation with a
Memory (2000).2 In fact, the original reads,
“an estimated 850 000 (range 300 000 to
1.4 million) adverse events might occur
each year in the NHS hospital sector . . .
some adverse events will be inevitable
complications of treatment.”
These figures are an extrapolation of two
studies, an American study in 1991, which
found that 3.7% of inpatient events led to
harmful adverse events, and an Australian
study, which gave a result of 16.6%.3 4 The
Department of Health averaged out these two
figures and applied the result to the number
of annual admissions to NHS hospitals. In
this way, we have been saddled with this
estimate of 850 000 errors that themedia and
politicians castigate us with.
The National Patient Safety Agency’s
website currently says that 900 000 events
are either harming or nearly harming
patients every year (note that it includes near
misses). As the Dr Foster unit found only
2.2% of episodes including a code for an
adverse event (less than either the United
States or Australia), can we look forward to
the end of this often quoted 850 000 figure?
Iain H Glencross general medical practitioner
140 Fitzwilliam Street, Huddersfield HD1 5PU
Iain.Glencross@GP-B85058.nhs.uk
Competing interests: None declared.
1 Aylin P, Tanna S, Bottle A, Jarman B. Dr Foster’s case notes.
How often are adverse events reported in English hospital
statistics? BMJ 2004;329:369. (14 August.)
2 Department of Health. An organisation with a memory.
London: DoH, 2000:11 (chapter 2, table 2.2).
3 Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR,
Lawthers AG, et al. Incidence of adverse events and negli-
gence in hospitalized patients; results of the Harvard
medical practice study 2.N Engl J Med 1991;324:377-84.
4 Wilson RM, Runciman WB, Gibberd RW, Harrison BT,
Hamilton JD. Quality in Australian health care study.Med J
Aust 1995;163:4:58-471.
No data were produced
Editor—No one should underestimate the
real risks of hospital treatment and in
particular of emergency surgery for elderly
patients. Adverse events in hospital are
under-recorded, but it should be recognised
that most complications are not due to medi-
cal blunders, and more often than not
mistakes are a potential, rather than an actual,
threat to the lives of patients. Recording mis-
takes should be transparent and effective in
reducing the level of risk to patients.
The publication by the Dr Foster team
does not produce any data on hospital deaths
but quotes as a reference a conference report
in 2001.1 Adverse events have been inter-
preted as an “unintended injury caused by
medical management rather than a disease
process, resulting in death, life threatening ill-
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ness, disability at the time of discharge, or a
prolongation of hospital stay.”
However, on subsequent clarification,
the diagnostic codes used in this study seem
to include inevitable and expected events.
Hospital episode statistics are at best difficult
to interpret, and, although considerable
efforts are being made to improve the valid-
ity of these data, they should be interpreted
with considerable caution. The alarming
headline in the Times is not based on estab-
lished fact,2 and, although the Dr Foster
organisation is committed to putting the
available data on medical care in the public
arena, the figure of 40 000 patients killed by
hospital blunders is not substantiated.
Furthermore, no evidence has been
advanced that mistakes in the NHS are any
more common than in any other healthcare
system. The medical profession continues to
improve the quality and safety of care to an
increasingly elderly population, and sur-
geons are anxious to reduce potentially pre-
ventable deaths to an absolute minimum.
The surgical community can reassure
patients that their safety is our number one
priority, but we are not complacent and are
constantly striving to do better.
Tom Bates chairman, Association of Breast Surgery
Association of Surgical Oncology, Royal College of
Surgeons of England, London WC2A 3PE
bates.tom@virgin.net
Competing interests: TB is fed up with Dr Foster.
1 Aylin P, Tanna S, Bottle A, Jarman B. Dr Foster’s case notes.
How often are adverse events reported in English hospital
statistics? BMJ 2004;329:369. (14 August.)
2 Blundering hospitals are killing 40 000 patients a year.
Times 2004 Aug 13.
Data relevant to patient safety should not
be presented alone and out of context
Editor—The publication of Dr Foster’s case
notes has generated considerable interest,1
but accurately quantifying patient safety
incidents is difficult. Methods of intensive
case note review provide estimates of
adverse events in acute hospitals that range
from 2.9% to 16.6%, but definitions,
methods, and health systems vary.2 3
The National Patient Safety Agency fully
supports Dr Foster’s conclusion that hospi-
tals should be encouraged to report
incidents. However, a full picture of patients’
safety is not possible from any one data
source: information is needed from a range
of sources for an accurate picture.
Furthermore, Dr Foster’s analysis tells us
nothing about what we need to change to
improve safety. Including data from systems
that collect information on causes and
prevention will be needed to support
improvement in patient safety.
The National Patient Safety Agency has
developed a national reporting and learning
system to enable healthcare staff to report
incidents anonymously. It is also setting up a
patient safety observatory to draw together
patient safety information from different
sources, including the reporting and learn-
ing system and studies such as this one from
Dr Foster. This will enable trends and
patterns to be spotted, as well as identifica-
tion of priorities for developing ways of
reducing patient risks.
To make a highly effective and valued
NHS safer for patients needs a concerted
effort across a range of organisations and
staff across the NHS. The National Patient
Safety Agency is committed to making this
happen.
Richard Thomson director of epidemiology and
research
National Patient Safety Agency, London W1T 5HD
Richard.thomson@npsa.nhs.uk
Competing interests: RT is an executive director
of the National Patient Safety Agency.
1 Aylin P, Tanna S, Bottle A, Jarman B. Dr Foster’s case notes.
How often are adverse events reported in English hospital
statistics? BMJ 2004;329:369. (14 August.)
2 Vincent C, Neale G, Woloshynowych M. Adverse events in
British hospitals: preliminary retrospective record review
BMJ 2001;322:517-9.
3 Baker GR, Norton PG, Flintoft V, Blais R, Brown A, Cox J,
et al. The Canadian adverse events study: the incidence of
adverse events among hospital patients in Canada. CMAJ
2004;170:1678-86.
Patients should be involved as partners
Editor—Dr Foster’s case notes on adverse
events in hospitals make alarming reading
for patients.1 However, evidence shows that
involving patients as partners in decisions
about and management of drug treatment
acts as a safeguard against errors.
Patients who understand their drug
treatment are better placed to pick up
prescribing, dispensing, or administration
errors. Documented examples include a
vigilant mother who prevented her child
being accidentally overdosed with insulin.2
Informed agreement about medicines,
when risks and benefits are understood,
reduces the possibility of patients varying
their dose or taking “drug holidays.”
Patients with several conditions treated
by different specialists risk being prescribed
drugs that interact. Currently, the best
safeguard is for patients themselves to have
a clear picture of all the drugs they are
taking.
A thorough, open discussion of medi-
cines is more likely to include over the coun-
ter and complementary remedies, which can
interact with prescribed drugs.
The initiative Ask About Medicines
Week (1-6 November) promotes partner-
ship between medicine users, carers, and
health professionals and is an important
contribution to improving patients’ safety.
We aim to achieve lasting change by
encouraging better communication,
improving the depth and quality of
medicines information, and changing
expectations so that asking questions about
medicines becomes the norm. This year the
campaign will include a fold out, credit card
sized record card for medicines—an impor-
tant safety tool. Further information is
available from www.askaboutmedicines.org
Joanne M Shaw director
Melinda Letts director
David Dickinson chairman
david.dickinson@consumation.com
Ask About Medicines Week, London SE1 7JN
Competing interests: None declared.
1 Aylin P, Tanna S, Bottle A, Jarman B. Dr Foster’s case notes.
How often are adverse events reported in English hospital
statistics? BMJ 2004;329:369. (14 August.)
2 I stopped a nurse giving my son lethal insulin dose. Daily
Mail 2002 May 23.
Authors’ reply
Editor—Our original text started with “It
has been suggested that an estimated
850 000 medical errors occur . . .” An
editorial decision by the BMJ changed the
text to a more definite “about 850 000
medical errors occur . . .” Unfortunately,
this change escaped our notice at the
proof stage. [A correction has since been
published.1]
Our intention was to describe what
information there was within hospital
episode statistics on adverse events. We
found a large number of events recorded
within hospital episode statistics but also
conclude that it is likely that they are under-
recorded.
We think that hospitals should be
encouraged to record such incidents. Hospi-
tal episode statistics were never designed as
a reporting system for adverse events and we
agree with Thomson that information from
a wide range of sources is needed for an
accurate picture of patient safety.
We concur with Shaw et al that involving
patients as partners in decisions about
medicines may act as a safeguard against
medication errors, but hospital episode
statistics offer little information on medica-
tion.Our analysis did not include deaths as it
would be difficult to ascribe any death to an
adverse event on the basis of the limited
information available within the data.
Paul Aylin
Alex Bottle
Shivani Tanna
Brian Jarman
Dr Foster Unit at Imperial, Department of
Epidemiology and Public Health, Imperial College,
London W2 1PG
p.aylin@imperial.ac.uk
Competing interests: PA and AB are funded by a
grant from Dr Foster.
Dr Foster is an independent research and
publishing organisation created to examine
measures of clinical performance.
1 Correction. Dr Foster’s case notes: How often are adverse
events reported in English hospital statistics? BMJ
2004;329:547. (4 September.)
The prince and the professor
Integrated approach is needed
Editor—The Prince of Wales’s keynote
speech to the joint symposium, which this
foundation, the National Cancer Research
Institute, and four of the United Kingdom’s
leading cancer charities (Marie Curie
Cancer Care, Bristol Cancer Help Centre,
Macmillan Cancer Relief, and Break-
through Breast Cancer) held in June,
attracted considerable media attention.1 2
Much of the interest was generated by inac-
curate and misleading reports of the
speech.
Letters
857BMJ VOLUME 329 9 OCTOBER 2004 bmj.com
We all want to understand what works
and what doesn’t, whether that be conven-
tional, complementary, or alternative
approaches to cancer.
As the Prince of Wales pointed out, if up
to 80% of patients with cancer try comple-
mentary or alternative treatments after diag-
nosis then surely it makes sense to
investigate their efficacy. The report by the
Science and Technology Select Committee
on Complementary and Alternative Medi-
cine in December 2000 recommended that
the Department of Health should provide
dedicated research funding in this area to
develop “centres of excellence.” It has been
good to see that, in response, the Depart-
ment of Health has made funding available
(particularly in its endeavour to build up
research capacity), but more
needs to be done.
The National Cancer
Research Institute’s estab-
lishment of a special interest
group on research into com-
plementary therapies is a sig-
nificant step forward in can-
cer and one that this
foundation strongly sup-
ports. As the Prince of Wales
said, it is essential to adopt a
collaborative approach to
cancer research—one that
takes into account all meth-
ods used by patients with
cancer.
Michael Fox chief executive
The Prince of Wales’s Foundation for Integrated
Health, London N7 8QJ
Michael@fihealth.org.uk
Competing interests: The Prince of Wales, is the
president of the Foundation for Integrated
Health.
1 Baum M. An open letter to the Prince of Wales: with
respect, your highness, you’ve got it wrong. BMJ
2004;329:118. (10 July.)
2 Prince of Wales. Speeches and articles: health. Available at:
www.princeofwales.gov.uk/speeches/
health_24062004.html (accessed 1 Oct 2004).
Which emperor is naked?
Editor—The crux of Baum’s argument
seems to be that the Prince of Wales should
not be advising people to embrace
“unproved” therapies.1 Baum seems to take
particular exception to the Prince of Wales’s
recent show of support for the so called
Gerson therapy, a cancer treatment based
on vegetable juices and coffee enemas.
The Gerson therapy is unproved in that
it has not been subjected to systematic study.
Whether it is of broad benefit to cancer
patients is simply not known. Was it so
wrong for the Prince of Wales to call for
more study in this area? But, even before the
evidence is in, Baum seems to dismiss nutri-
tional therapy out of hand and describes the
experience of patients with cancer who are
apparently cured by it as an “urban myth.”
So far as the potential benefits of a
treatment are concerned, absence
of evidence does not necessarily mean
evidence of absence.
Baum’s views on naturally oriented can-
cer treatments seem to be based not on sci-
entific objectivity (as he seems to assert) but
prejudice. It is perhaps ironic that he
indirectly cautions the Prince of Wales about
letting his personal beliefs prejudice his
advice.
A strong subtext in Baum’s letter is the
notion that conventional cancer treatments
are based on sound scientific ground. But is
this really so? Chemotherapy is often
recommended for several types of cancer for
which there is no clear evidence of benefit.
Currently, cancer affects about one in three
of the population and kills one in four.
These bald statistics mean that the great
majority of people diagnosed with cancer
will die from it. This is hardly a ringing
endorsement of conven-
tional cancer treatment.
The dawn of the infor-
mation age and a rising
desire for self empowerment
mean that, like it or not,
people are becoming
increasingly knowledgeable
about the principles, prac-
tice, and politics of medicine.
More and more, it seems,
they are growing cautious of
conventional medicine and
“expert” opinion. I suspect
Baum’s views will do little to
restore people’s faith in
these things. Varman
congratulates the professor on having the
courage to point out that the emperor has
no clothes.2 Perhaps he might like to clarify
which emperor he is referring to?
John P Briffa doctor and writer
London
drjbriffa@aol.com
Competing interests: None declared.
1 Baum M. An open letter to the Prince of Wales: with
respect, your highness, you’ve got it wrong. BMJ
2004;329:118. (10 July.)
2 Varman S. Bravo! Electronic response to: An open letter to
the Prince of Wales. bmj.com 2004. http://
bmj.bmjjournals.com/cgi/eletters/329/7457/
118?[66224 (accessed 1 Sep 2004).
With respect, Professor Baum, you’ve got
it wrong
Editor—In his personal view on the Prince
of Wales’s speech, Baum takes the view that
only evidence based practices should be
used, such as those of orthodox medicine.1
Brighthope reminds us that 85% of medical
treatments are not supported by solid
scientific evidence and only about 1-5% of
articles published in medical journals are
“scientifically sound,” concluding that poor
medical evidence supports most medical
practices, including surgery (Baum’s spe-
cialty).2 Accusing complementary and alter-
native medicine of being unproved is
hypocritical.
The Prince of Wales did not promote
any alternative treatments. Rather, he men-
tioned examples of what he had heard from
patients who used juices or the Gerson diet
to highlight the importance of looking at the
evidence of such anecdotal reports.
Baum has “much time for complemen-
tary and alternative medicine that offers
improvements in quality of life or spiritual
solace.” Perhaps he has difficulty believing
that it may also have biological actions and
cure disease (the domain of orthodox
medicine)? That biological methods are the
domain of medicine implies that behind
the debate on complementary and alterna-
tive medicine are issues of professional
power and medical autocratism, as well as
ignorance and prejudice.
Some complementary and alternative
therapies have side effects, can be danger-
ous, and are a waste of money, effort, and
energy. But until that can be said with confi-
dence, we cannot take away from patients
the increased hope that such treatments can
provide or their right to decide what their
treatment will include. If all were great with
orthodox medicine, would patients need to
turn elsewhere?
Our duty and responsibility is to protect
patients from harm and provide more
choice and broaden the limits of medicine
by integrating complementary therapies
that are potentially important in managing
illness.
Alexander Molassiotis reader in cancer and
supportive care
School of Nursing Midwifery and Health Visiting,
University of Manchester, Manchester
alex.molassiotis@man.ac.uk
Competing interests: AM was present at the con-
ference where the Prince of Wales delivered his
speech.
1 Baum M. An open letter to the Prince of Wales: with
respect, your highness, you’ve got it wrong. BMJ
2004;329:118. (10 July.)
2 Brighthope I. Do you trust orthodox medicine and doubt
complementary therapies? Some observations about
proven therapies and scientific evidence in medicine.
www.thegreenline.com.au/Resources/Brighthope.htm
(accessed 1 Sep 2004).
With respect, professor, the Prince of
Wales is not so wrong
Editor—Baum’s open letter criticised the
unproved alternative therapies that Prince
Charles was endorsing.1
Why is food seen as alternative?
Although 13 glasses of carrot juice and cof-
fee enemas may be yet scientifically
unproved, food as a remedy for chronic dis-
ease is not. My father is working on a prod-
uct that involves fruit on the basis of his own
theories of carcinogenesis. But of course he
can’t claim that it kills cancer cells because it
is a food supplement and therefore not
regarded as medicinal.
Baum thinks that high profile figures
making sweeping statements on matters
they are not qualified in is not helpful, but
people are dying, so isn’t the sharing of
thoughts beneficial, however unfounded?
Baum himself has criticised orthodox medi-
cine, so maybe he would agree that the so
called alternative therapies working in
conjunction with so called orthodox treat-
ments should be given a chance? The body
is evolved to metabolise natural compounds
not synthesised drugs, so shouldn’t nature
have a turn, at the very least to work in a
complementary manner?
Prince Charles
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I believe the Prince of Wales wants to
help. He is the president of the Foundation
for Integrated Health and a campaigner for
remedies. He is looking ahead and embraces
change and chances in the hope of saving
lives.
Patients with cancer hang on to Baum’s
every statement—he should respect the work
of others who can prove their findings.
Bobby K Potter student in politics, University of
Nottingham
Asda Hulme, South Manchester M15
ldyxrkp@nottingham.ac.uk
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Heretics unite
Editor—Well done Michael Baum, you
deserve a knighthood at the very least for
putting your head on the block yet again
and having the courage to say what most of
us believe, but usually feel too cowardly to
express in the presence of the Royals.1 See
you in the Tower.
From your fellow heretic.
Lesley J Fallowfield professor of psycho-oncology
Brighton and Sussex Medical School, Brighton
BN1 9QG
L.J.Fallowfield@sussex.ac.uk
Competing interests: LF is a known collaborator
of Michael Baum.
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Science is worth the effort
Editor—I write in response to Baum’s
personal view.1 As a doctor struggling to
learn the art of molecular biology (through
which doctors and scientists seek to under-
stand illnesses and develop new treatments),
I can attest to the huge complexity of the
subject. Science is difficult. Science requires
great effort on the part of
those who wish to under-
stand it.
Because it is so difficult, I
fully understand the human
temptation to seek under-
standing of the world’s
mysteries in a more intuitive,
simpler way. Alas, such over-
simplifications only reveal
mirages. Medical science,
like all technologies, relies
on the cold analysis of
hard data: would we have
mobile phones and space-
ships if physicists had
ignored the facts in front of
them?
In contrast with professional scientists,
most of us, the prince and his defenders
included, do not have the ability, training,
skills, or years of effort fully to understand
the complexities of science. Contradiction
of scientific research, without the founda-
tion of extensive scientific education is
prejudiced folly.
Arrogant are those, whoever they are,
who discount the lengthy application of
powerful scientific brains, because they are
unable to understand the complexities of
the subject. Facts are facts, however hard to
grasp.
Luke Devey MRC/RCSEd clinical research training
fellow
Tissue Injury and Repair Group, MRC Centre for
Inflammation Research, Medical School 6th Floor,
University of Edinburgh, Edinburgh EH8 9AG
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Summary of responses
Editor—Professor Baum’s open letter in
response to the Prince of Wales’s speech at a
research symposium on complementary
therapies and cancer care at the Royal
College of Obstetricians and Gynaecologists
sparked off some 80-odd responses.1 Practi-
tioners of conventional medicine and of
alternative and complementary medicine
(sometimes both), former and current
patients (who have much to say to
recommend both approaches), journalists,
social workers, clerics, and scientists world-
wide all responded.
Those who agree unanimously with
Professor Baum reject Prince Charles’s pro-
posals in no uncertain terms. But a count
reveals that they are not the majority—and
neither are those who fervently defend
exclusively complementary approaches to
cancer care. Most correspondents, regard-
less of which side of the fence they may be
on, interpret the prince’s speech as advocat-
ing an integrated approach, not the aban-
donment of reason, asking for complemen-
tary and alternative medicines to undergo
the same rigorous trials as conventional
treatments. The prince and the professor in
the same boat?
Some correspondents
are concerned that the media
bias public opinion through
a lack of critical reporting
and by giving certain fash-
ionable treatments and
celebrities more column
inches than conventional sci-
entists, thus giving them a
prominence they do not
deserve. Maybe alternative
health columns should be
published with a health
warning?
Correspondents who
have personal experience of
all manner of complemen-
tary and alternative therapies are particu-
larly convinced that these may be tomor-
row’s science and are mostly in favour of
conducting trials. Many correspondents
have no objection to rigorous scientific test-
ing but point out that funding may be a
problem or that such funds might be used
more effectively elsewhere.
A few correspondents think that the two
directions cannot be integrated and comple-
mentary therapies can therefore not be
trialled. Their measurements are different
and cannot satisfy the criteria of modern
medicine, although they may coexist com-
fortably as long as neither tries to claim
supremacy.
Several correspondents remind us that
traditional Chinese medicine, ayurveda, and
many other traditional medical systems
around the world that we today call
“complementary” or “alternative” are in fact
thousands of years old, whereas our own
“conventional” approach has been around
for a mere few hundred years. Consequently,
the debate about what science is and about
scientific methods, objectivity, deduction,
reproducibility, generating hypotheses, and
the arbitrariness of statistical measures
forms most of the debate. There are no
proved results in science as all facts are to a
greater or lesser degree provisional.
Or, to quote Krishna Badami, a specialist
in transfusion medicine: “Today’s orthodoxy
could well end up as tomorrow’s heresy and
vice versa.”
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BMJ
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Human touch could be saved
by using robots
Editor—When I had surgery at one of the
best hospitals in the United States, I saw my
surgeon twice for two minutes. After the first
day, I rarely saw a nurse. But when I walked
around, the nurses were busy documenting
information on computers. In the meantime
when my fellow patients found out I was a
doctor, they barraged me with questions
about their illnesses and operations.
In these days when the bureaucrats
won’t pay you until you write every tiny
detail down, may I suggest that we use
robots to document the details, so we get
paid, rather than get the robots to allow
doctors to check and interact with their
patients after surgery?1 Let the doctors and
nurses do what they went into medicine for
in the first place: to care for people in those
low tech and low paying jobs such as
talking, rubbing where it hurts, and giving
sympathy and comfort to the families who
visit.
Nancy K O’Connor doctor
Pawhuska Indian Health Center, Pawhuska, OK
74056, USA
NOcon6929@aol.com
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